<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82280">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01878448</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-02-II</org_study_id>
    <nct_id>NCT01878448</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Anlotinib Hydrochloric Capsule in STS Patients</brief_title>
  <acronym>ALTN/STS</acronym>
  <official_title>Phase 2 Study of Anlotinib Hydrochloric Capsule in Advanced Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug
      Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,
      Ltd.

      ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2
      and VEGFR3. It has the obvious resistance to new angiogenesis. The protocol is to explore
      ALTN for the effectiveness of advanced soft tissue sarcoma and security.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>tumor size</measure>
    <time_frame>each 42 days  up to 48 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the effectiveness of Anlotinib Hydrochloric Capsule by enhanced CT scan every two cycles. Refer to recist 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>each 21 days  up to 48 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>blood examination, urine examination, stool examination, blood biochemical (ALT, AST, TB(total bilirubin), DB, BUN, Cr, blood electrolyte), electrocardiogram (ecg), thyroid function, the function of blood coagulation, etc</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib Hydrochloric Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloric Capsule</intervention_name>
    <arm_group_label>Anlotinib Hydrochloric Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Faild in introditional treatmeat, Mainly includes:MFH/liposarcoma/leiomyosarcoma/SS
             and others(MPNST/Fibrosarcoma/CCS/ASPS/AS/ES; 2.Receiveed at least one chemotherapy
             regimens treatment; 3.18-70years, ECOG:0-2,Expected survival period &gt;3 months;
             4.HB≥100g/L,ANC(Absolute Neutrophil Count) ≥1.5×109/L；PLT

               -  80×109/L ,BIL/Cr in normal range,ALT/AST(aspartate aminotransferase
                  )≤1.5*ULN(for hepatic metastases,ALT/AST(aspartate aminotransferase )≤5*ULN)
                  ;TG≤ 3.0mmol/L，cholesterol≤7.75mmol/L; LVEF

               -  LLN. 5.Used contraceptive during the study and after 6 months; 6.Volunteer.

        Exclusion Criteria:

          -  1. Received vascular endothelial growth inhibitor type of targeted therapy; 2.With
             the second cancer; 3.Participated in other clinical trials in four weeks; 4.Received
             in other radiotherapy or chemotherapy treatment in four weeks; 5.AE&gt;1 6.Has influence
             of oral drugs; 7.Brain metastases, spinal cord compression, cancerous meningitis;
             8.Any serious or failed to control the disease 9.Artery/venous thrombotic;
             10.Coagulant function abnormality; 11.Arteriovenous thrombosis event; 12.Hitory of
             psychiatric drugs abuse or a mental disorder; 13.Immunodeficiency history;
             14.Concomitant diseases.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinwan Wang, doctor</last_name>
    <phone>010-87788842</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yihebali Chi, doctor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 1st affiliated hospital of bengbu medical college</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rongsheng Zheng, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinwan Wang, doctor</last_name>
      <phone>010-87788842</phone>
    </contact>
    <investigator>
      <last_name>Jianqiang Cai, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinwan Wang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yihebali Chi, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Jishuitan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohui Niu, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiwei Fang, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianchun Yu, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenzhi Bi, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Wenzhi Bi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Province Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyong He, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Meidical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Zhu, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gansu Province Tumor Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianming Song, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shusen Wang, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi medical university affiliated tumor hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongkui Lu, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin medical university affiliated tumor hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guofan Qu, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Province Tumor Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Sun, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaonan Hong, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai 6th People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Yao, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guowen Wang, doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 15, 2013</lastchanged_date>
  <firstreceived_date>May 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
